ÁÖ¸Þ´º

Ȩ¾ÆÀÌÄÜ  >  À̽´

[¿¬±¸] ¸é¿ªÇ×¾ÏÄ¡·á ³»¼º ±Øº¹ ½Ç¸¶¸® ¹ß°ß

±è¼ºÈ­ ±âÀÚksh2@healthi.kr ÀÔ·Â : 2019-07-30 17:14  | ¼öÁ¤ : 2019-07-30 17:14

³×À̹ö ÆäÀ̽ººÏ ¹êµå ±¸±Û Æ®À§ÅÍ ÇÉÅÍ·¹½ºÆ® īī¿À½ºÅ丮 īī¿À¸µÅ© Àμ⠴ٿî·Îµå È®´ë Ãà¼Ò

 

½ºÆÃ ÀÛ¿ëÁ¦¸¦ ÀÌ¿ëÇÑ ¸é¿ªÇ×¾ÏÄ¡·á¹ý
ÀÚ·á=°úÇбâ¼úÁ¤º¸Åë½ÅºÎ

 

[Çコ¾Ø¶óÀÌÇÁ ±è¼ºÈ­ ±âÀÚ] ¿ì¸® ¿¬±¸ÁøÀÌ  ¾Ï ³»ºÎÀÇ ºñÁ¤»óÀûÀÎ Ç÷°üÀ» Â÷´ÜÇÏ´Â ´Ü¹éÁú ½ºÆÃ(Sting)ÀÇ ¿ªÇÒÀ» ±Ô¸íÇÏ°í ¸é¿ªÇ×¾ÏÄ¡·áÀÇ ³»¼º ±Øº¹À» À§ÇÑ ½Ç¸¶¸®¸¦ Á¦½ÃÇß´Ù.

 

°úÇбâ¼úÁ¤º¸Åë½ÅºÎ´Â ºÐ´çÂ÷º´¿ø Ç÷¾×Á¾¾ç³»°ú ±èÂù·ÀüÈ«Àç ±³¼ö·¾çÇѳª ¹Ú»ç ¿¬±¸ÆÀÀÌ À̰°Àº ¿¬±¸¼º°ú¸¦ ³Â´Ù°í 30ÀÏ ¹àÇû´Ù.

 

¸é¿ª¼¼Æ÷¿¡ ÀÖ´Â ½ºÆÃÀº ¾Ï¼¼Æ÷¿¡¼­ ³ª¿Â DNA Á¶°¢À» ŽÁöÇØ ¸é¿ª¼¼Æ÷°¡ ¾Ï¼¼Æ÷¸¦ °ø°ÝÇϵµ·Ï Áغñ½ÃŰ´Â ¼¾¼­ ¿ªÇÒÀ» ÇÑ´Ù. ½ºÆÃÀ» Ȱ¼ºÈ­½ÃŰ´Â ÀÛ¿ëÁ¦(agonist)¿Í °ü·ÃÇÑ ¸é¿ªÇ×¾ÏÁ¦ Àӻ󿬱¸°¡ ´Ù±¹Àû Á¦¾à»ç¸¦ Áß½ÉÀ¸·Î ÁøÇàµÇ°í ÀÖ´Ù. ÇÏÁö¸¸ 70%ÀÇ È¯ÀÚ´Â ³»¼ºÀ» °®°í ÀÖ¾î ¸é¿ª¼¼Æ÷°¡ ¾Ï¼¼Æ÷¸¦ ÀÎÁöÇÏÁö ¸øÇϰųª ¹«ºÐº°ÇÏ°Ô »ý¼ºµÈ ¾ÏÇ÷°üÀÌ ¸é¿ª¼¼Æ÷°¡ Á¾¾ç ³»·Î ħÅõÇÏ´Â °ÍÀ» ¹æÇØÇØ ¹®Á¦°¡ µÆ´Ù.

 

¿¬±¸ÁøÀº ±âÁ¸¿¡ Àß ¾Ë·ÁÁø ¸é¿ª¼¼Æ÷¿¡¼­°¡ ¾Æ´Ï¶ó ¾ÏÇ÷°ü ¼¼Æ÷¿¡¼­ÀÇ ½ºÆÃÀÇ ¿ªÇÒÀ» ±Ô¸íÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ³»¼ºÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â ½Ç¸¶¸®¸¦ ã¾Æ³Â´Ù.

 

¿¬±¸ÁøÀº 400¿© ¸íÀÇ ³­Ä¡¾Ï ȯÀÚ ¾ÏÁ¶Á÷À» ºÐ¼®ÇØ ¾ÏÇ÷°ü¿¡¼­ ½ºÆÃÀ» Ȱ¼ºÈ­½Ãų °æ¿ì ¾Ï ³»ºÎÀÇ ºñÁ¤»óÀûÀÎ Ç÷°üÀÌ Â÷´ÜµÅ Á¾¾çÀÇ ¼ºÀå°ú ÀüÀ̰¡ ¾ïÁ¦µÇ´Â °ÍÀ» È®ÀÎÇß´Ù. ½ºÆÃ ÀÛ¿ëÁ¦°¡ ÇØ·Î¿î ¾ÏÇ÷°üÀ» ¾ïÁ¦ÇÏ´Â ÇÑÆí ¸é¿ª¹ÝÀÀ¿¡ À̷οî Ç÷°ü¸¸À» ³²°Ü ¸é¿ª¼¼Æ÷°¡ ¾Ï ³»ºÎ·Î Àß Ä§ÅõÇÒ ¼ö ÀÖµµ·Ï Çß´Ù. ÀÌ´Â ½ºÆÃ ÀÛ¿ëÁ¦¿Í ÇÔ²² ¾ÏÇ÷°ü½Å»ý¾ïÁ¦Á¦¿ÍÀÇ º´¿ë»ç¿ë °¡´É¼ºÀ» Á¦½ÃÇÑ °ÍÀÌ´Ù.

 

±èÂù ºÐ´çÂ÷º´¿ø Ç÷¾×Á¾¾ç³»°ú ±³¼ö
»çÁø=ºÐ´çÂ÷º´¿ø

½ÇÁ¦ ¸é¿ªÇ×¾ÏÁ¦¿¡ ¹ÝÀÀÀ» º¸ÀÌÁö ¾Ê´ø ³»¼º¾ÏÀÌ ½ºÆÃ ÀÛ¿ëÁ¦, ¾ÏÇ÷°ü½Å»ý¾ïÁ¦Á¦, ¸é¿ªÇ×¾ÏÁ¦¸¦ »ïÁß º´¿ëÇÏ¿´À» ¶§ ¾à 60%¿¡¼­ ¼Ò½ÇµÆ´Ù. ¶ÇÇÑ ¾ÏÇ÷°ü ³» ½ºÆÃ ´Ü¹éÁúÀÌ ¸¹À»¼ö·Ï ´õ ÁÁÀº ¿¹Èĸ¦ °¡Áö´Â µî ¾ÏÇ÷°ü¿¡¼­ÀÇ ½ºÆÃÀÇ ¿ªÇÒÀÌ Á¾¾ç ³» ¸é¿ª¹ÝÀÀ°ú ¹ÐÁ¢È÷ °ü·ÃµÊÀ» ¾Ë¾Æ³Â´Ù.

 

±èÂù ±³¼ö´Â “¸é¿ªÇ×¾ÏÁ¦ÀÇ È¿°ú¸¦ Áõ°­½ÃŰ°í ³»¼ºÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·áÀü·«À» È®ÀÎÇÑ °Í”À̶ó¸ç “½ºÆÃ ÀÛ¿ëÁ¦¸¦ ÀÌ¿ëÇÑ ¸é¿ªÇ×¾ÏÄ¡·á´Â ½ÅÀå¾Ï, °£¾Ï, ÃéÀå¾Ï, ¹æ±¤¾Ï°ú °°Àº ³­Ä¡¼º ¾Ï Ä¡·á¿¡ ´õ¿í È¿°úÀûÀÎ Ä¡·á¹ýÀÌ µÉ ¼ö ÀÖÀ» °Í”À̶ó°í ¼³¸íÇß´Ù.

 

À̹ø ¿¬±¸´Â °úÇбâ¼úÁ¤º¸Åë½ÅºÎ ±âÃÊ¿¬±¸»ç¾÷(½ÅÁø¿¬±¸) ¹× ¹ÙÀÌ¿ÀÀÇ·á±â¼ú°³¹ß»ç¾÷ÀÇ Áö¿øÀ¸·Î ¼öÇàµÆÀ¸¸ç ÀÓ»óÀÇÇÐ ºÐ¾ß ±¹Á¦ÇмúÁö <Àú³Î ¿Àºê Ŭ¸®´ÏÄà Àκ£½ºÆ¼°ÔÀ̼Ç(Journal of Clinical Investigation)> 7¿ù 25ÀÏÀÚ·Î °ÔÀçµÆ´Ù.

 

 

 

 

******¾Æ·¡´Â ³í¹® ¿øº» ÀϺΠ¹ßÃ麻(Downloaded from Journal of Clinical Investigation)

 

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

 

Hannah Yang, Won Suk Lee, So Jung Kong, Chang Gon Kim, Joo Hoon Kim, Sei Kyung Chang, Sewha Kim, Gwangil Kim, Hong Jae Chon, and Chan Kim

 

abstract

 

The stimulator of interferon genes (STING) signaling pathway is a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING is expressed in vasculatures, but its role in tumor angiogenesis has not been elucidated. Here we investigated STING-induced tumor vascular remodeling and the potential of STING-based combination immunotherapy. Endothelial STING expression was correlated with enhanced T-cell infiltration and prolonged survival in human colon and breast cancer. Intratumoral STING activation with STING agonists (cGAMP or RR-CDA) normalized tumor vasculatures in implanted and spontaneous cancers, but not in STING-deficient mice. These were mediated by upregulation of type I/II interferon genes and vascular stabilizing genes (e.g., Angpt1, Pdgfrb, and Col4a). STING in non-hematopoietic cells is as important as STING in hematopoietic cells to induce a maximal therapeutic efficacy of exogenous STING agonist. Vascular normalizing effects of STING agonists were dependent on type I interferon signaling and CD8+ T cells. Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune checkpoint blockade (αPD-1 or αCTLA-4), leading to complete regression of immunotherapy-resistant tumors. Our data show that intratumoral STING activation can normalize tumor vasculature and the tumor microenvironment, providing a rationale for combining STING-based immunotherapy and anti-angiogenic therapy.

 

 

¡Ø Ãâó  Journal of Clinical Investigation


ksh2@healthi.kr

#Çコ¾Ø¶óÀÌÇÁ #±è¼ºÈ­±âÀÚ #°úÇбâ¼úÁ¤º¸Åë½ÅºÎ #±âÃÊ¿¬±¸»ç¾÷ #sting #½ºÆÃ #¸é¿ª¼¼Æ÷ #dna #¸é¿ªÇ×¾ÏÄ¡·á #³»¼º±Øº¹ #³»¼º #±èÂù #ºÐ´çÂ÷º´¿ø